Mary Jo Fidler to Breast Neoplasms
This is a "connection" page, showing publications Mary Jo Fidler has written about Breast Neoplasms.
Connection Strength
0.165
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
Score: 0.165